In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Antimicrobial Agents and Chemotherapy
Ernest Asante-AppiahJoseph A Kozlowski

Abstract

Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds. Ruzasvir inhibited HCV RNA replication with 50% effective concentrations (EC50s) of 1 to 4 pM in Huh7 or Huh7.5 cells bearing replicons for HCV genotype 1 (GT1) to GT7. The antiviral activity was modestly (10-fold) reduced in the presence of 40% normal human serum. The picomolar potency in replicon cells extended to sequences of clinical isolates available in public databases that were synthesized and tested as replicons. In GT1a, ruzasvir inhibited common NS5A resistance-associated substitutions (RASs), with the exception of M28G. De novo resistance selection studies identified pathways with certain amino acid substitutions at residues 28, 30, 31, and 93 across genotypes. Substitutions at position 93 were more common in GT1 to -4, while changes at position 31 emerged frequently in GT5 and -6. With the exception of GT4, the reintroduction of selected RASs conferred a ≥100-fold potency reduction in the antiviral activity of ruzasvir. Common RASs from other classes of direct-acting ...Continue Reading

References

Mar 1, 1993·Antimicrobial Agents and Chemotherapy·M N PrichardC Shipman
Dec 9, 2000·Science·K J BlightC M Rice
Jan 16, 2004·Gastroenterology·Takanobu KatoTakaji Wakita
Jan 19, 2008·Antiviral Research·Xiao TongRobert Ralston
May 1, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE1 Study Team
Jun 30, 2010·Antimicrobial Agents and Chemotherapy·Robert A FridellMin Gao
Jul 29, 2011·The Journal of General Virology·Dike QiuRobert A Fridell
Aug 3, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert A FridellMin Gao
Aug 8, 2012·Antimicrobial Agents and Chemotherapy·Mohsan SaeedCharles M Rice
Mar 2, 2013·Expert Opinion on Investigational Drugs·David Alan Herbst, K Rajender Reddy
Oct 16, 2013·ChemMedChem·Craig A CoburnSteven W Ludmerer
Jun 1, 2014·Current Opinion in Virology·Precious J Lim, Philippe A Gallay
Apr 12, 2012·ACS Medicinal Chemistry Letters·Steven HarperNigel J Liverton
Jul 2, 2014·Antimicrobial Agents and Chemotherapy·Constance N Wose KingeCharles M Rice
Oct 28, 2014·Expert Opinion on Pharmacotherapy·Guido Stirnimann
Dec 3, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Marc BourlièrePaul Castellani
Dec 8, 2014·The Journal of General Virology·Douglas Ross-Thriepland, Mark Harris
Aug 8, 2015·Current Opinion in HIV and AIDS·Valeria CentoCarlo Federico Perno
Aug 26, 2015·Antimicrobial Agents and Chemotherapy·Rong LiuAnita Y M Howe
Nov 26, 2015·Expert Review of Gastroenterology & Hepatology·Marc BourlièrePhilippe Halfon
Dec 24, 2015·Viruses·Asma Ahmed, Daniel J Felmlee
Dec 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eric LawitzJames Witek
Feb 7, 2016·Bioorganic & Medicinal Chemistry Letters·Anilkumar G NairJoseph A Kozlowski
May 18, 2016·Bioorganic & Medicinal Chemistry Letters·Wensheng YuJoseph A Kozlowski
Jun 11, 2016·Bioorganic & Medicinal Chemistry Letters·Wensheng YuJoseph A Kozlowski
Jun 11, 2016·Bioorganic & Medicinal Chemistry Letters·Wensheng YuJoseph A Kozlowski
Jul 8, 2016·Expert Opinion on Drug Metabolism & Toxicology·Isabella EspositoVicente Soriano
Jul 11, 2016·Bioorganic & Medicinal Chemistry Letters·Wensheng YuJoseph A Kozlowski
Jul 18, 2016·Bioorganic & Medicinal Chemistry Letters·Michael P DwyerJoseph A Kozlowski
Aug 29, 2016·Bioorganic & Medicinal Chemistry Letters·Wensheng YuJoseph A Kozlowski
Sep 17, 2016·Bioorganic & Medicinal Chemistry Letters·Ling TongJoseph A Kozlowski
Sep 24, 2016·Expert Opinion on Drug Safety·Mohamed El KassasGamal Esmat
Oct 27, 2016·Current Opinion in Infectious Diseases·Daniel M Forton
Oct 26, 2016·Bioorganic & Medicinal Chemistry Letters·Ling TongJoseph A Kozlowski

❮ Previous
Next ❯

Citations

Jul 28, 2020·Frontiers in Cellular and Infection Microbiology·Shaheen KhanNaga Suresh Veerapu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.